Weilersbach N mit Kommentar von Rieckmann P

2. Februar 2021
Long-term benefit of early multiple sclerosis treatment with interferon beta-1b: lower disease activity, delayed disability progression, improved overall survival
J Med Drug Rev 2012;2;31-39 (Review-Artikel in deutscher Sprache) Multiple sclerosis (MS) often starts in early adulthood und thereafter typically takes a course over several decades. However, clinical studies in MS with usual treatment periods of one to three years cover this long-term course only inadequately. In contrast to this, […]